Protagonist Therapeutics (PTGX) Expected to Announce Earnings on Tuesday

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Protagonist Therapeutics to post earnings of ($0.50) per share and revenue of $30.44 million for the quarter.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $2.07. The company had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. On average, analysts expect Protagonist Therapeutics to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Protagonist Therapeutics Price Performance

Shares of PTGX stock traded up $0.52 during mid-day trading on Friday, hitting $45.51. 644,080 shares of the stock traded hands, compared to its average volume of 862,840. Protagonist Therapeutics has a 52-week low of $25.23 and a 52-week high of $60.60. The stock's fifty day moving average is $46.37 and its two-hundred day moving average is $42.82. The stock has a market cap of $2.82 billion, a P/E ratio of 17.11 and a beta of 2.65.

Analyst Ratings Changes

PTGX has been the topic of a number of research analyst reports. BMO Capital Markets boosted their price target on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. JPMorgan Chase & Co. raised their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Wedbush reissued an "outperform" rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a report on Friday, March 28th. JMP Securities restated a "market outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.44.

Insider Activity

In other news, insider Arturo Md Molina sold 30,514 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the sale, the insider now directly owns 83,892 shares of the company's stock, valued at $4,676,140.08. This represents a 26.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the sale, the chief executive officer now owns 540,260 shares in the company, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,532 shares of company stock valued at $3,665,786 in the last quarter. 5.40% of the stock is currently owned by company insiders.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.